Dimerix (ASX: DXB) — Company Overview, News & Financial Data
Dimerix is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for inflammatory diseases, with a primary focus on rare kidney and respiratory conditions.
Dimerix
Dimerix is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for inflammatory diseases, with a primary focus on rare kidney and respiratory conditions. Based in Fitzroy, Victoria, the company utilizes proprietary drug discovery technology to target G-protein coupled receptor interactions involved in disease pathology. Its principal late-stage clinical candidate is undergoing global Phase 3 trials for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder causing progressive renal failure. Additional clinical and preclinical development programs target diabetic kidney disease, acute kidney injury, and chronic obstructive pulmonary disease.
Snapshot
Operations
Products and/or services of Dimerix
- Focal Segmental Glomerulosclerosis Therapeutics: Phase 3 clinical development of an oral chemokine receptor CCR2 antagonist administered alongside standard-of-care angiotensin II receptor blockers to reduce proteinuria and preserve kidney function in patients diagnosed with rare inflammatory kidney disorders.
- Diabetic Kidney Disease Therapies: Phase 2 clinical evaluation investigating dual-targeted receptor inhibition therapy designed to address kidney inflammation and progressive renal function decline in adult patients suffering from diabetic nephropathy receiving stable background treatment regimens.
- Chronic Obstructive Pulmonary Disease Therapies: Preclinical and early-stage clinical research evaluating small-molecule candidates targeting G-protein coupled receptor complexes to suppress lung inflammation and tissue damage in patients experiencing chronic obstructive pulmonary disease and related respiratory conditions.
- Acute Kidney Injury Therapeutics: Preclinical formulation and development of targeted anti-inflammatory molecules aimed at preventing cellular injury and preserving organ tissue integrity in patients suffering from acute kidney injury during critical medical complications.
- Drug Discovery Platform: Proprietary assay technologies designed to identify and characterize G-protein coupled receptor heteromer interactions, enabling functional screening and rational design of novel pharmaceutical compounds targeting complex inflammatory signaling pathways across disease indications.
Dimerix executive team
- Nina WebsterCEO, MD & Director
- Michael TonroeCFO & Company Secretary
- Robert ShepherdChief Operating Officer
- David Everett FullerChief Medical Officer
- Kevin Donald George PflegerChief Scientific Advisor
Latest news about Dimerix
Dimerix completes first 100 patients in ACTION3 Phase 3 trial
AustraliaDimerix reaches four year patient clinical trial milestone
AustraliaDimerix draws down $17M funding facility
AustraliaDimerix secures Mexican patent for DMX-652
AustraliaDimerix secures $34M funding facility
AustraliaDimerix secures new asset for US$5M
Australia
Recent announcements
What Dimerix (DXB) has told the market, newest first.
- Dimerix at Canaccord Drug & Device and Ignite Conferences
- First Patient Reaches Four Years in DMX-200 Clinical ProgramPrice sensitive
- Dimerix Investor Webinar
- Dimerix Licenses DMX200 to Everest for China and Asia RegionPrice sensitive
Key financials
Reported results for Dimerix, in AUD.
- Market cap
- 129.1M
- Revenue (TTM)
- 6.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 4.4M | -37.2M | -29.8M | |
| 1.3M | -36.3M | -13.3M | |
| 583.5K | -25.2M | -17.1M | |
| 36.8K | -22.8M | -13.8M |